Want to see CRMD full AI Analyst Report?
CRMD Stock Chart & Stats
$8.56
-$0.18(-2.24%)
At close: 4:00 PM EDT
$8.56
-$0.18(-2.24%)
Day’s Range― - ―
52-Week Range$6.13 - $13.02
Previous CloseN/A
Volume625.29K
Average Volume (3M)1.00M
Market Cap
$618.88M
Enterprise Value$613.76M
Total Cash (Recent Filing)$256.69M
Total Debt (Recent Filing)$145.15M
Price to Earnings (P/E)3.3
Beta1.18
Next Earnings
Nov 11, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.41
Shares Outstanding77,944,320
10 Day Avg. Volume1,221,867
30 Day Avg. Volume1,004,932
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.07
Price to Sales (P/S)2.69
P/FCF Ratio4.85
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.33
Enterprise Value/Gross Profit1.60
Enterprise Value/Ebitda2.46
Forecast
1Y Price Target
$14.60Price Target Upside70.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.5
Revenue Forecast (FY)$337.06M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue And Profitability GrowthThe sharp increase in revenue and adjusted EBITDA indicates meaningful commercial scale and operating leverage across the combined business. If sustained, this growth can strengthen internal funding capacity, support investment in DefenCath and REZZAYO, and improve the company’s ability to absorb execution costs.
Strong Cash Generation And LiquiditySubstantial cash generation and liquidity provide financial flexibility during the commercial expansion. The resources can fund sales investments, clinical and regulatory activity, and potential REZZAYO preparation without making the company immediately dependent on external capital, while also supporting balance-sheet resilience.
Expanded Commercial AccessCoverage of all five leading U.S. dialysis providers gives DefenCath access to the most important channels serving eligible hemodialysis patients. Multi-year agreements can support recurring product demand, improve distribution reach, and create a stronger foundation for broader adoption as provider pilots and ordering patterns develop.
Bears Say
Reimbursement And Ordering UncertaintyChanging reimbursement rules can affect provider economics, ordering behavior, and the pace of DefenCath adoption even when clinical demand remains intact. Uncertainty around Medicare Advantage and the final ESRD rule may delay purchasing decisions, complicate forecasting, and create pressure on realized revenue over coming quarters.
Higher Operating InvestmentThe materially higher cost base raises the level of revenue and gross profit needed to preserve earnings momentum. Acquisition integration, commercial investment, and expanded R&D may be strategically useful, but they can reduce near-term operating leverage if product growth or REZZAYO progress does not offset the spending.
Limited Durability HistoryRecent profitability is strong, but the short history of positive earnings makes long-term durability less certain than the latest margins suggest. Earlier losses and minimal revenue indicate that the current financial profile depends on sustaining product adoption and execution, leaving greater risk if reimbursement or commercial conditions change.
Cormedix News
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $6.13 and its highest was $13.02 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $618.88M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Nov 11, 2026 which is in 15 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Aug 13, 2026. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.238 by $0.052.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is -0.11.
How many shares outstanding does Cormedix have?
Cormedix has 77,944,320 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of $0.29 in its last earnings report, beating expectations of $0.238. Following the earnings report the stock price went up 14.648%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cormedix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.60 (70.56% Upside)
$14.60 (70.56% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 78%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 288.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.59%
12-Months-Change
Fundamentals
Return on Equity
44.64%
Trailing 12-Months
Asset Growth
257.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cormedix
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
CRMD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution (notably large revenue and adjusted EBITDA growth), solid cash generation, strategic commercial agreements with all top 5 dialysis providers, and meaningful pipeline progress highlighted by positive Phase III data for REZZAYO and an anticipated sNDA submission. These positives were tempered by higher operating expenses (driven by the Melinta acquisition and planned commercial investments), uncertainty around post-TDAPA ordering patterns and final ESRD reimbursement, and the limited current visibility on the impact of the new LDO pilot and Medicare Advantage contracting. On balance, the magnitude of the operational and financial wins (large YoY revenue and EBITDA growth, strong cash flow, clear regulatory/pipeline momentum) outweighs the near-term expense increases and reimbursement uncertainties.View all CRMD earnings summariesCRMD Stock 12 Month Forecast
Average Price Target
$14.60
▲(70.56% Upside)
Technical Analysis
MiMedx Group
―
Fennec Pharmaceuticals
―
Pharming Group
―
Valneva
―
Turn Therapeutics Inc
―
Ownership Overview
2.96% Insiders
10.27% Mutual Funds
0.96% Other Institutional Investors
68.59% Public Companies and
Individual Investors